Equities

TheraCryf PLC

TCF:LSE

TheraCryf PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)0.75
  • Today's Change0.00 / 0.00%
  • Shares traded26.78k
  • 1 Year change-80.26%
  • Beta1.5893
Data delayed at least 20 minutes, as of May 17 2024 12:35 BST.
More ▼

Financials data is unavailable for this security.

Cash flow in GBPView more

In 2023, TheraCryf PLC increased its cash reserves by 10.86%, or 490.00k. Cash Flow from Investing totalled 4.62m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 4.13m for operations while cash used for financing totalled .
Cash flow per share-0.0122
Price/Cash flow per share--
Book value per share0.0143
Tangible book value per share0.0142
More ▼

Balance sheet in GBPView more

TheraCryf PLC has a strong Balance Sheet and has consistently grown its cash reserves over the last four years to total 5.00m.
Current ratio10.39
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.